FBXO43 promotes cell cycle progression in cancer cells through stabilizing SKP2
Cancer Letters · 2024
DOI: 10.1016/j.canlet.2024.216848 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Liyun Zheng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, Chin…. Hauptthemen laut MEDLINE: Cell Cycle, F-Box Proteins, Proto-Oncogene Proteins c-akt, S-Phase Kinase-Associated Proteins. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Chinese Academy of Meteorological Sciences.
Abstract (Originalsprache)
FBXO43 is a member of the FBXO subfamily of F-box proteins, known to be a regulatory hub during meiosis. A body of data showed that FBXO43 is overexpressed in a number of human cancers. However, whether and how FBXO43 affects cell cycle progression and growth of cancer cells remain elusive. In this study, we provide first piece of evidence, showing a pivotal role of FBXO43 in cell cycle progression and growth of cancer cells. Specifically, FBXO43 acts as a positive cell cycle regulator with an oncogenic activity in variety types of human cancer, including non-small cell lung cancer, hepatocellular carcinoma and sarcoma. Mechanistically, FBXO43 interacts with phosphorylated SKP2 induced by AKT1, leading to reduced SKP2 auto-ubiquitylation and subsequent proteasome degradation. Taken together, our study demonstrates that FBXO43 promotes cell cycle progression by stabilizing SKP2, and FBXO43 could serve as a potential anti-cancer target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
- Qilu Hospital of Shan Dong University, Jinan, Shandong Province, China.
- Cancer Institute of the Second Affiliated Hospital and Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China; Zhejiang University Cancer Center, Hangzhou, China; Research Center fo…
- Department of Biochemistry, Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. Electronic address: wangzhen@imb.pumc.edu.cn.
Förderung
- National Natural Science Foundation of China
- Chinese Academy of Meteorological Sciences
Zitieren
APA
Zheng, L., Shen, J., Chen, Y., Lin, J., Li, P., Zhao, X., Ren, H., Sun, Y., & Wang, Z. (2024). FBXO43 promotes cell cycle progression in cancer cells through stabilizing SKP2. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.216848
Vancouver
Zheng L, Shen J, Chen Y, Lin J, Li P, Zhao X, et al. FBXO43 promotes cell cycle progression in cancer cells through stabilizing SKP2. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.216848
BibTeX
@article{Zheng2024,
author = {Zheng, Liyun and Shen, Jiajia and Chen, Yang and Lin, Jingyu and Li, Pengyu and Zhao, Xiaoli and Ren, Hangjiang and Sun, Yi and Wang, Zhen},
title = {FBXO43 promotes cell cycle progression in cancer cells through stabilizing SKP2},
journal = {Cancer Letters},
year = {2024},
doi = {10.1016/j.canlet.2024.216848}
}
EUVIMED